Longevity.Technology UNLOCKED

Guests:Dr Lara Briden Naturopathic doctor and Bestselling AuthorInstagram: www.instagram.com/larabriden/Website: www.larabriden.com/Dr Molly MaloofEducator, Author, and Founder of AdamoInstagram: www.instagram.com/drmolly.co/?hl=enWebsite: https://drmolly.co/______________________Sponsor: StrideStride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science. Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.Link: www.getstride.com/unlocked/______________________What if the key to female longevity has been hiding in plain sight?In this episode, Phil Newman and Dr Nina Patrick sits down with Dr Lara Briden, evolutionary biologist and hormone expert, and Dr Molly Maloof, functional medicine practitioner, to explore the metabolic, hormonal, and evolutionary factors that shape female longevity.They dive into the often-overlooked role of iron in perimenopause and post-menopause, the hidden epidemic of insulin resistance, and the nuanced balance of fatty acids for cellular health. Lara reframes menopause as an adaptive stage that supports the survival of the next generation, while Molly explains why metabolic flexibility is one of the most powerful tools for long-term health.Together, they discuss practical strategies women can use across their lifespan—from iron management and blood markers to gut health, nutrition, and exercise—as well as exciting breakthroughs in biotechnology, peptides, and regenerative medicine that could extend female healthspan in the next decade.In this episode, you’ll learn:Why managing iron levels is crucial for longevity, especially in perimenopause and post-menopause.How regular ovulatory cycles and pregnancy shape long-term metabolic and reproductive health.The hidden role of insulin resistance and simple blood markers that can flag early metabolic dysfunction.The importance of omega-6, omega-3, and saturated fats balance for cell membrane and neurological health.How evolutionary biology explains menopause as a “superpower” for human survival.Practical steps for women to optimize metabolism, exercise, and nutrient intake across their lifespan.The emerging role of biotechnology, regenerative medicine, and peptides in extending female healthspan.If you want to take control of your metabolic health, understand menopause as a stage of strength, and learn strategies to optimize female longevity across the lifespan, this is a conversation you don’t want to miss.Subscribe for weekly episodes that explore longevity science, healthspan optimization, and the emerging strategies and interventions shaping the future of female health.______________________Hosts:Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

Sponsor: StrideStride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science. Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.Link: https://www.getstride.com/unlocked/______________________In this week’s Longevity News Roundup, Phil Newman and Nina Patrick explore new research shaping the future of longevity science, from macrocyclic peptides targeting previously undruggable diseases to hyperbaric oxygen therapy in performance and longevity, and South Korea emerging as a global biotech hub.Santa Cruz-based Unnatural Products raised $45 million in Series B funding and secured a potential $1.7 billion collaboration with Novartis. The company develops macrocyclic peptide therapeutics, molecules that combine the selectivity of biologics with the cell permeability of small molecules, targeting age-related cardiometabolic, inflammatory, and immunological diseases.Hyperbaric oxygen therapy (HBOT) is moving into the longevity and biohacking space, with companies like HPO.TECH’s launching chambers for performance and wellness settings. Early anecdotal reports suggest improvements in sleep and cognition, but long-term, large-scale clinical evidence is still limited.South Korea is quietly becoming a major longevity hub. Eli Lilly and Roche have invested nearly $1 billion in local biotech infrastructure, including incubation programs and advanced hospitals. Serotonin Centers launches a partner program bringing medically supervised longevity services directly into gyms across the US. By integrating diagnostics, therapies, and biomarker-driven programs into existing fitness spaces, this model increases accessibility and scalability for preventive health, bridging the gap between clinical longevity interventions and everyday fitness routines.The Aging Research & Drug Discovery (ARDD) conference is relocating to Boston in 2026, placing one of the world’s leading longevity science meetings directly in the heart of a dense biotech, pharma, and academic corridor. This move strengthens connections between research, startups, and decision-makers, accelerating deal flow and industry engagement while highlighting the mainstreaming of aging biology into drug development pipelines.Evolve Science has launched a US-based longevity peptide platform designed around medically supervised protocols targeting core aging pathways, including tissue repair, mitochondrial function, and metabolic regulation. By combining proper manufacturing, analytics, and clinical follow-up, the platform aims to separate validated therapeutic peptides from gray-market hype, addressing the growing demand for safe, evidence-based interventions in the longevity space.______________________News & References:Engineering longevity with the ZEUGMA hyperbaric chamber → https://longevity.technology/news/engineering-longevity-with-the-zeugma-hyperbaric-chamber/Biotech lands $45m to drug the undruggable → https://longevity.technology/news/biotech-lands-45m-to-drug-the-undruggable/Gyms tap medical longevity with Serotonin Centers’ model → https://longevity.technology/news/gyms-tap-medical-longevity-with-serotonin-centers-model/Lilly commits $500m in South Korea’s rise as longevity hub → https://longevity.technology/news/lilly-commits-500m-in-south-koreas-rise-as-longevity-hub/ARDD 2026 to relocate to Boston → https://longevity.technology/news/ardd-2026-to-relocate-to-boston/Evolve Science launches longevity peptide platform → https://longevity.technology/news/evolve-science-launches-longevity-peptide-platform/______________________Hosts:Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

Guests:Dr. Dave Rabin MD, PhDFounder of Apollo NeuroLinkedin: www.linkedin.com/in/drdavemdphd/Website: https://apolloneuro.com/Dr Pedram ShojaiFounder of The Urban MonkInstagram:www.instagram.com/drpedramshojai/Website: https://theurbanmonk.com/___________________Sponsor: Stride Stride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science. Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount. Link: www.getstride.com/unlocked/___________________What if stress isn’t something to eliminate… but something to train?Phil Newman and Dr. Nina Patrick sit down with neuroscientist and psychiatrist Dr. Dave Rabin and physician and Qigong teacher Dr. Pedram Shojai to explore how resilience is built through the nervous system. From circadian rhythms and recovery to breathwork, movement, and biofeedback, they explain why longevity depends less on constant performance and more on structured restoration.Dave explains how chronic uncertainty activates threat responses in the brain, disrupting sleep, focus, immunity, and emotional regulation. Predictability, safety signals, and vagus nerve activation help restore recovery pathways that support cognition and long term health.Pedram shares how attention, perception, and daily pacing influence vitality. Practices like mindfulness, Qigong, and intentional routines help shift the body out of survival mode, while technology can support awareness but cannot replace foundational habits.Together, they show that resilience is not a hack. It is a rhythm between effort and recovery that trains the brain to adapt, learn, and age well.In this episode, you’ll learn:How chronic stress alters brain function, sleep, and long-term healthWhy recovery should be scheduled like performanceHow breathwork and somatic practices activate safety pathwaysThe role of circadian rhythm in resilience and cognition Where wearable technology helps and where it doesn’tIf you want to understand how stress regulation shapes cognitive performance, sleep quality, and healthy aging, this episode connects neuroscience with practical daily habits you can actually apply.Subscribe for weekly episodes that explore longevity science, healthspan optimization, and the systems shaping how we live longer and better.___________________Hosts: Phil Newman: https://qrco.de/bgXpNYNina Patrick: https://qrco.de/bgXpKn

In this week’s Longevity News Roundup, Phil Newman and Nina Patrick explore new research shaping the future of longevity science, from neuroprotective obesity drugs and fasting-mimicking supplements to bionic vision implants and AI-driven athletic longevity platforms.A growing body of research suggests that GLP-1 receptor agonists may influence brain aging. A recent review in the Journal of Clinical Investigation highlights how these drugs could support neuronal energy production, stimulate autophagy, reduce chronic inflammation, and improve synaptic resilience. Early human studies show signals of preserved brain metabolism in Alzheimer’s patients, though larger clinical trials are still underway.New diagnostic tools for neurodegeneration are also emerging. Startup Amydis received funding from the National Institute on Aging to develop an eye-based molecular imaging test for Amyotrophic Lateral Sclerosis (ALS). Their approach uses fluorescent tracers that bind to TDP-43, allowing early disease signatures to be detected through routine retinal imaging.In metabolic health, Mimio Health reported results from a randomized controlled trial testing a fasting-mimetic supplement. The formulation includes Spermidine and Nicotinamide, compounds that rise during prolonged fasting. Over eight weeks, participants showed improvements in fasting glucose and lipid markers, suggesting the possibility of replicating certain fasting signals without caloric restriction.Hardware innovation is also advancing longevity care. Science Corporation raised $230 million to scale its PRIMA retinal implant, a tiny photovoltaic chip placed beneath the retina. Working with specialized glasses that project infrared patterns, the implant converts light signals into electrical stimulation, restoring basic visual perception for patients with advanced geographic atrophy.In sports longevity, Capriroso launched a new training intelligence system designed for endurance athletes. By combining sleep metrics, heart rate variability, training load, and recovery data, the platform aims to optimize performance across decades rather than short-term race cycles.Finally, emerging research into sleep and circadian biology continues to reshape dementia prevention strategies. Studies show that disrupting circadian rhythms can trigger inflammatory changes in brain immune cells known as microglia, which may contribute to neurodegenerative disease. Researchers are also studying hibernating animals to understand how certain species tolerate extreme metabolic stress and reverse neurological damage, offering potential new targets for human therapies._____________________News & References:GLP-1 drugs hint at protection against neurodegeneration → https://longevity.technology/news/glp-1-drugs-hint-at-protection-against-neurodegeneration/Amydis lands NIA funding to detect ALS in the eye → https://longevity.technology/news/amydis-lands-nia-funding-to-detect-als-in-the-eye/Fasting mimetic shows metabolic effects in trial → https://longevity.technology/news/fasting-mimetic-shows-metabolic-effects-in-trial/Science Corp lands $230m to commercialize vision restoration chip → https://longevity.technology/news/science-corp-lands-230m-to-commercialize-vision-restoration-chip/Capriroso launches platform for athlete longevity → https://longevity.technology/news/capriroso-launches-platform-for-athlete-longevity/Sleep rhythms and dementia risk link emerges → https://longevity.technology/news/sleep-rhythms-and-dementia-risk-link-emerges/_____________________Hosts:Phil Newman: ⁠⁠⁠⁠https://qrco.de/bgXpNY⁠⁠⁠⁠Nina Patrick: ⁠⁠⁠⁠https://qrco.de/bgXpKn⁠

Guests: Dr James GoolnikFounder of Optimal Dental HealthInstagram: www.instagram.com/jamesgoolnik/?hl=enWebsite: www.optimaldentalhealth.co.uk/Dr Aoife StackCo-founder of Airway SchoolInstagram: www.instagram.com/doctor_aoife/?hl=enWebsite: www.airwayschool.co.uk______________________What if your mouth was more than just teeth and gums? What if it silently shaped your sleep, metabolism, immunity, and brain health?Phil Newman and Dr. Nina Patrick sit down with Dr. Aoife Stack and Dr. James Goolnik, two clinicians taking a systems-level approach to oral health. They explore how the mouth and airway influence sleep, metabolism, inflammation, and brain function, and why dental care isn’t just about teeth.Aoife explains the importance of nasal breathing, tongue posture, and myofunctional therapy for optimal sleep and overall health. James highlights practical strategies around sugar reduction, saliva balance, and oral hygiene that protect against decay and inflammation. Together, they unpack the science connecting oral health with the microbiome, nitric oxide production, and systemic resilience.The conversation dives into childhood and adult interventions—from simple nasal tape and tongue exercises to orthodontics and myofunctional therapy—showing how small adjustments can create meaningful improvements in energy, cognitive function, and long-term health. They also discuss how lifestyle factors, dietary habits, and awareness of daily routines can prevent cascading health issues before they start.This episode emphasizes that longevity is more than exercise and diet. Supporting oral and airway health, understanding systemic connections, and applying practical, sustainable habits are essential pillars for extending healthspan, optimizing sleep, and improving quality of life.In this episode, you’ll learn:Why nasal breathing, tongue posture, and oral function are foundational to sleep, energy, and brain healthHow simple practices like tongue scraping, nasal tape, and myofunctional exercises can improve airway and postureThe role of saliva, oral microbiome, and diet in preventing decay, gum disease, and systemic inflammation- How small childhood and adult interventions can create long-term benefits for airway function, sleep quality, and resilienceStrategies for sustainable sugar reduction and habit stacking to protect oral and systemic healthIf you care about improving long-term health, sleep, and energy, and want actionable advice grounded in evidence-based science, this conversation is a must-listen.Subscribe for weekly episodes that explore longevity science, preventative strategies, and the emerging tools and interventions that help us understand and optimize the body’s natural systems for lasting healthspan.______________________Hosts:Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick explore the latest breakthroughs shaping longevity and proactive healthcare. From government-backed healthspan trials to next-generation brain wearables, smartphone-based health screening, ovarian longevity research, and nanotech biosensing, this episode connects science, innovation, and real-world impact.The US government committed $144 million through ARPA-H’s PROSPR program to fund research proving that aging can be treated in humans. Cambrian BioPharma received $30.8 million for trials of a next-generation rapamycin analog, while Linnaeus Therapeutics received $22 million to explore oncology-derived drugs showing age-related benefits. PROSPR also funds biomarker development and trial infrastructure to enable rapid, large-scale healthspan studies.Temple is developing a head-worn wearable that continuously monitors cerebral blood flow and brain activity. This next-generation device moves beyond wrist-worn fitness trackers, providing real-time insight into cognitive function, fatigue, and brain health for both elite athletes and general populations.Berlin-based YOU(th) closed a $4.5 million round for its smartphone-based health screening platform. Using AI and photoplethysmography, the platform analyzes face videos, voice recordings, and other sensors to assess 50 digital biomarkers in under two minutes, offering a scalable, longitudinal view of health outside the clinic.Mainstream pharma is also advancing longevity research. Richter acquired Celmatix’ ovarian biology assets to expand therapies targeting ovarian aging. Slowing ovarian decline could impact fertility, bone health, cardiovascular risk, and cognitive resilience, reinforcing women’s health as a central longevity focus.Data on billionaire longevity shows wealth alone offers minimal lifespan extension. Male billionaires live about four years longer than peers, while female billionaires have life expectancy below long-lived populations. The analysis highlights the importance of investing in scientific research over relying solely on lifestyle or capital.Finally, Swiss startup Xsensio is developing a nanotech-enabled continuous biosensing platform. This minimally invasive skin sensor tracks metabolites, electrolytes, and inflammatory markers in real time, offering a path toward proactive, biomarker-driven healthcare and continuous monitoring of intrinsic capacity._____________________News & References:ARPA-H pours millions into healthspan-focused human trials → https://longevity.technology/news/arpa-h-pours-millions-into-healthspan-focused-human-trialsWearable startup Temple secures $54m for brain monitoring → https://longevity.technology/news/wearable-startup-temple-secures-54m-for-brain-monitoring/YOU(th) lands funding for smartphone-based preventive health screening → https://longevity.technology/news/youth-lands-funding-for-smartphone-based-preventive-health-screening/Richter sharpens ovarian aging focus following Celmatix asset deal → https://longevity.technology/news/richter-sharpens-ovarian-aging-focus-following-celmatix-asset-deal/How billionaires die → https://longevity.technology/news/how-billionaires-die/Nanotech startup lands funding for continuous biosensing platform → https://longevity.technology/news/nanotech-startup-lands-funding-for-continuous-biosensing-platform/_____________________Hosts:Phil Newman: ⁠⁠⁠https://qrco.de/bgXpNY⁠⁠⁠Nina Patrick: ⁠⁠⁠https://qrco.de/bgXpKn

Guests:Allen Law Founder and CEO of MORROWLinkedin:https://www.linkedin.com/in/allenlawphg/Website:https://morrow.health/Dr William TanClinical Governance Officer of MORROWLinkedin: https://www.linkedin.com/in/dr-william-tan-05438649/Website: https://morrow.health/______________________Sponsor: StrideStride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science. Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.Link:https://www.getstride.com/unlocked/______________________What if longevity wasn’t a treatment… but a system you live inside every day?In this episode, Phil Newman sits down with Allen Law, founder and CEO of Morrow, and Dr William Tan, physician-neuroscientist and Chief Governance Officer of Morrow, to explore a new model of preventive healthcare designed around daily behavior, measurable biology, and community support.They discuss why modern medicine often reacts to disease rather than preventing it, how lifestyle medicine can be structured into actionable programs, and why most people fail to act on their health data even after testing. Allen explains how Morrow combines diagnostics, coaching, and artificial intelligence to translate biomarkers into habits, while William shares how his personal journey through disability and elite sport shaped his philosophy of proactive health.Together, they examine accessibility in longevity care, the economics of preventive medicine, and why community engagement may be as important as any clinical intervention. The conversation also looks at Singapore’s evolving health ecosystem and how technology could scale personalized care beyond elite clinics.In this episode, you’ll learn:Why preventive healthcare often fails despite widespread testingHow Morrow connects diagnostics directly to daily lifestyle interventionsThe role of AI in turning health data into consistent habit changeWhy community and purpose influence long term health outcomesHow accessibility could reshape the longevity clinic industryWhat Singapore’s healthcare model reveals about future global systemsWhy small consistent habits outperform short term health resolutionsIf you want to understand how healthcare may shift from treating illness to designing wellbeing, and what real world longevity infrastructure could look like, this conversation offers a practical view of the future of healthspan.Subscribe for weekly episodes exploring longevity science, emerging biotech, and the innovations shaping the future of human health.______________________Hosts:Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick explore the latest discoveries transforming longevity science. From invisible nanoplastics crossing the blood-brain barrier to first-of-its-kind Klothea mRNA human trials, wearable lactate sensors, and AI models targeting aging-linked inflammation, this episode connects science, innovation, and real-world impact.Recent research shows that nanoplastics, ultra-small fragments of degraded plastic closer in size to viruses than visible debris, are accumulating in human brain tissue. Age does not predict accumulation, and higher concentrations appear in tissues affected by Alzheimer’s and vascular dementia. Klothea has launched a phase 1b human trial for their AKL003 mRNA therapy, aiming to boost levels of the longevity-associated protein alpha-Klotho. Conducted in Prospera, Honduras, the study measures epigenetic clocks, inflammatory and metabolic markers, mitochondrial function, sleep, and patient-reported quality of life. This represents one of the first human longevity trials designed around lifespan as the primary endpoint rather than disease. In sports and metabolic monitoring, PointFit is developing a wearable sweat patch that continuously tracks lactate, cortisol, creatine, and glucose. Lactate serves as a real-time biomarker for exercise intensity and fatigue, bridging elite athlete optimization and general population healthspan. Early adoption is expected in high-performance sports, but applications in rehab and clinical aging are promising.Regulatory innovation continues with the FDA officially ending the “two trial dogma.” One pivotal, rigorously designed trial may now suffice for drug approval, lowering barriers for therapies targeting aging processes and biomarker-driven endpoints. This shift could shave three to five years off development timelines and reduce costs by tens of millions, accelerating the path for human longevity drugs.Finally, AI is moving from broad discovery to targeted intervention. Scienta Lab unveiled EVA, a multimodal AI platform mapping inflammatory networks tied to aging, aiming to design precision anti-inflammatory therapies. Rather than simply accelerating existing pharma pipelines, platforms like EVA could guide the development of highly personalized interventions tailored to an individual’s inflammatory signature, tissue context, and age.The Longevity Show has confirmed Hertility as Strategic Content and Scientific Lead Partner for the Women’s Health Summit at its inaugural 2026 event in London. Hertility will co-lead the scientific framing and programme development of the Summit. The partnership positions female biology not as a thematic sidebar, but as a structural lens through which longevity science and infrastructure must increasingly be designed.______________________News & References:Nanoplastics found in the brain raise new aging questions → https://longevity.technology/news/nanoplastics-found-in-the-brain-raise-new-aging-questions/Klothea initiates longevity-focused human trial of klotho therapy → https://longevity.technology/news/klothea-initiates-longevity-focused-human-trial-of-klotho-therapy/Seveno backs PointFit wearable patch → https://longevity.technology/news/seveno-backs-pointfit-wearable-patch/FDA rewrites drug approval rules and longevity stands to gain → https://longevity.technology/news/fda-rewrites-drug-approval-rules-and-longevity-stands-to-gain/Scienta’s new AI model targets aging-linked inflammation → https://longevity.technology/news/scientas-new-ai-model-targets-aging-linked-inflammation/Hertility announced as Women’s Health Partner for Longevity Show → https://longevity.technology/news/hertility-announced-as-womens-health-partner-for-longevity-show/______________________Hosts:Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

Guest: Alexander Zhavoronkov Founder, CEO and CBO at Insilico MedicineLinkedin: www.linkedin.com/in/zhavoronkov/Website: https://insilico.com/______________________What if the biggest breakthrough in longevity wasn’t a single drug… but a faster way to discover them?In this episode, Phil Newman and Dr Nina Patrick sit down with Alex Zhavoronkov, founder and CEO of Insilico Medicine, to explore how artificial intelligence is reshaping biotechnology, from target discovery to clinical trials.They discuss why advanced diagnostics may currently outperform most longevity interventions, how AI platforms design entirely new molecules, and why no longevity drug has yet proven efficacy in humans despite promising animal data. Alex explains how modern biotech companies balance aging research with traditional disease treatment, and why the first real longevity therapeutics will likely emerge as side benefits of drugs built for specific conditions.Together, they examine the reality behind GLP-1 drugs, long term safety testing, and the limits of predictive algorithms. The conversation also looks ahead to brain computer interfaces, multimodal biological models, and the possibility of pharmaceutical superintelligence accelerating medical progress within the next decade.In this episode, you’ll learn:Why early diagnostics may currently be the most reliable longevity strategy.How AI can design drug candidates in months instead of years.- Why most longevity drugs succeed in animals but fail to prove benefits in humans.How disease focused therapeutics could become future aging interventions.What GLP-1 drugs reveal about the future of longevity medicine.The real role of clinical trials in validating AI generated therapies.How next generation technologies like brain computer interfaces could extend healthy lifespan.If you want to understand how artificial intelligence is changing medicine, what real longevity therapeutics may look like, and why the future of healthspan depends on both biology and computation, this is a conversation you don’t want to miss.Subscribe for weekly episodes exploring longevity science, emerging biotech, and the innovations shaping the future of human health.______________________Hosts:Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

Sponsor: StrideStride helps people understand and improve their wellbeing and longevity through personalized DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science. Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.Link: https://www.getstride.com/unlocked/______________________In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick explore the latest breakthroughs shaping healthspan and longevity. From oral GLP-1 pills transforming obesity and metabolic care, to early gene therapy results in aging dogs, and Amazon integrating biomarker-driven longevity insights into primary care, this episode covers innovation, risk, and opportunity across human and animal longevity.Novo Nordisk and Eli Lilly are moving forward with oral versions of their GLP-1 drugs, potentially bringing millions more patients onto treatment. Pills are easier to access than injections, but counterfeiting risks are rising. GLP-1 therapies are evolving beyond weight loss into long-term metabolic health interventions, targeting cardiovascular, joint, and chronic pain outcomes.London-based GenFlow Biosciences released preliminary data from its SIRT6 gene therapy in aged dogs. All treatment groups showed improved survival, muscle mass, and frailty scores. This dual approach addresses companion animal health while acting as a translational model for human aging interventions.In digital health, Amazon One Medical is rolling out biomarker-driven insights powered by LifeForce’s longevity platform. This signals a growing shift in how consumer and clinical longevity data will influence behavior, outcomes, and healthcare delivery.In consumer trends, global PR firm Edelman highlights the rise of the longevity generation. Their Longevity Lab initiative shows that people 55 and older control more than half of global consumer spending, yet receive only a fraction of marketing budgets. Brands are beginning to rethink products, campaigns, and services for older, active, high-spending consumers, a growing business opportunity in the health, finance, hospitality, and lifestyle sectors.Israeli neurotech company QuantalX launched the Delphi MD system in the US, a non-invasive brain function assessment combining transcranial magnetic stimulation, EEG, and AI analytics. Already deploying at Penn, Mass General, UCSF, and UT Dallas, the test has a reimbursement code, potentially shifting brain health monitoring from reactive to preventative care.Gimv, a European investment firm, signaled a pullback from early-stage aging biotech, citing long timelines and unpredictable ROI. Capital is now shifting toward technology-enabled services, diagnostics, and digital longevity platforms where returns are faster and more measurable. ______________________News & References:What Gimv’s biotech pullback says about aging markets → https://longevity.technology/news/what-gimvs-biotech-pullback-says-about-aging-markets/Are global brands ready for longevity? → https://longevity.technology/news/are-global-brands-ready-for-longevity/New functional brain assessment system rolls out in the US → https://longevity.technology/news/new-functional-brain-assessment-system-rolls-out-in-the-us/As obesity drugs go oral and access grows, so do fakes → https://longevity.technology/news/as-obesity-drugs-go-oral-and-access-grows-so-do-fakes/Genflow reveals early data from SIRT6 gene therapy trial in dogs → https://longevity.technology/news/genflow-reveals-early-data-from-sirt6-gene-therapy-trial-in-dogs/Amazon makes longevity move with Lifeforce collab → https://longevity.technology/news/amazon-makes-longevity-move-with-lifeforce-collab/______________________Hosts:Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

Guest: Christian DrapeauFounder + Chief Science Officer of STEMREGENInstagram: https://www.instagram.com/stemcellchristian/Website: https://www.stemregen.co/______________________Sponsor: StrideStride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science. Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.Link: https://www.getstride.com/unlocked/______________________What if your body had a repair system that could predict and prevent age-related disease?Phil Newman and Dr. Nina Patrick sit down with Christian Drapeau, a researcher and expert in stem cells and regenerative biology. Christian explains how stem cells act as the body’s natural repair system, why measuring them could become a key biomarker for health, and how lifestyle factors, diet, and specific plant compounds can optimize their activity.They explore the science behind stem cell release, how exercise, fasting, meditation, sauna, and cold exposure support regeneration, and the emerging technologies helping stem cells reach their full potential. Christian also discusses targeted applications for heart repair, joint health, and other tissues, as well as the future of accessible stem cell measurement.This conversation highlights that supporting longevity goes beyond lifestyle hacks or clinical treatments. Christian’s research shows that understanding stem cell biology, preparing the body’s “terrain” for repair, and aligning interventions with evidence-based science are all critical for extending healthspan and improving long-term quality of life.In this episode, you’ll learn:Why stem cells are the cornerstone of the body’s repair systemHow measuring stem cells could predict age-related disease and track healthLifestyle and diet strategies to naturally boost stem cell releaseHow technology like PMF, sauna, and cold exposure works with stem cellsTargeted stem cell applications for heart, joints, and tissue repair careIf you care about protecting your long-term health and want to understand how science, technology, and clinical strategies intersect to shape the future of healthspan, this is a conversation you don’t want to miss.Subscribe for weekly episodes that explore longevity science, healthspan optimization, and the emerging strategies, interventions, and technologies helping us understand and harness the body’s natural repair systems.______________________Hosts:Phil Newman: https://qrco.de/bgXpNYNina Patrick: https://qrco.de/bgXpKn

Sponsor: StrideStride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science. Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount. Link: https://www.getstride.com/unlocked/______________________In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick explore breakthroughs shaping healthspan and longevity, from pioneering longevity drugs for dogs to one-shot gene therapies for ALS, AI-driven longevity data platforms, and innovations in environmental detox.Loyal, backed by Laura Deming’s Age1 Fund and other investors, raised $100 million Series C to advance LOY002, a daily pill aimed at extending the healthy lifespan of senior dogs. The drug has cleared two of three FDA hurdles, and its STAY trial will enroll 1,300 dogs across 70 clinics, potentially setting a regulatory precedent for aging as an approvable indication.Decoding Longevity Trends, a new AI-native platform tracking over 600 longevity-focused companies, including pipelines, mechanisms of action, and clinical stages. The system features a chatbot for complex queries and aims to accelerate insights for investors, pharma, and operators in the longevity ecosystem.Cambiotics, a Copenhagen-based startup, raised $4 million to develop 46and, a probiotic supplement designed to help the body eliminate PFAS (“forever chemicals”). Early research shows specific gut bacteria can bind PFAS, with human trials expected in the US this year, marking a step forward in exposome-based longevity interventions.In neurodegeneration news, Vector Y dosed its first patient in a Phase 1 trial for VTX002, a one-time gene therapy targeting TDP43 pathology in ALS. This vectorized antibody approach installs a long-term antibody factory in the CNS, potentially transforming treatment from repeated dosing to durable, one-shot interventions and extending to other neurodegenerative conditions.The biohacking and self-managed health sector is projected to hit $216 billion by 2035, led by North America. Wearables, diagnostics, genetics, and personalized health platforms are driving adoption, while longevity and neuroscience increasingly intersect with consumer-driven biohacking practices.Backed by a five-year, $3.3 million federal award, a new research initiative at Oregon Health & Science University (OHSU) aims to develop a retinal screening tool that could flag the earliest biological signals of Alzheimer’s using nothing more than an eye drop and a quick scan.______________________News & References:Loyal raises $100m as canine longevity drug nears approval → https://longevity.technology/news/loyal-raises-100m-as-canine-longevity-drug-nears-approval/VectorY doses first patient in ALS gene therapy trial → https://longevity.technology/news/vectory-doses-first-patient-in-als-gene-therapy-trial/Longevity.Technology unveils DLT – the intelligence platform for longevity → https://longevity.technology/news/longevity-technology-unveils-dlt-the-intelligence-platform-for-longevityDanish startup aims to remove ‘forever chemicals’ from the body → https://longevity.technology/news/danish-startup-aims-to-remove-forever-chemicals-from-the-body/Biohacking market projected to top US$216 billion by 2035 → https://longevity.technology/news/biohacking-market-projected-to-top-us216-billion-by-2035/New retinal screening targets Alzheimer’s before memory loss → https://longevity.technology/news/new-retinal-screening-targets-alzheimers-before-memory-loss/______________________Hosts:Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

Guests:Carolyn Ringel, JD, MBEConsultant and Instructor for Harvard Medical School Center for BioethicsLinkedIn: https://www.linkedin.com/in/carolyn-baker-ringel-35378431/David Barzilai, MD, PhD, MBA, MS, DipABLMFounder and CEO of Barzilai Longevity ConsultingLinkedIn: https://www.linkedin.com/in/agingdoc/Website: https://www.barzilaiconsulting.com/david________________Longevity ethics? What if extending healthspan required rethinking not just medicine, but society itself?Phil Newman and Dr. Nina Patrick sit down with Carolyn Ringel, a bioethicist at Harvard Medical School, and Dr. David Barzilai, a longevity medicine physician. They explore how aging research and geroscience can address urgent health issues like heart disease, diabetes, cancer, and dementia, while highlighting the ethical responsibilities of science and medicine.Carolyn emphasizes that studying aging is not an either-or with addressing current health crises; by understanding aging, we can better prevent and treat age-related diseases. She also explores how healthcare funding, housing, and social infrastructure can be designed to support longer, healthier lives, creating a society where longevity benefits everyone.David explains the importance of trusted patient-doctor relationships, scientific literacy, and emerging interventions like aging biomarkers, cellular reprogramming, and regenerative medicine. He highlights the potential of integrated, systems-based approaches and AI-driven research to accelerate the development of safe, effective longevity strategies.This conversation highlights that longevity is not just about supplements, exercise, or clinical interventions. Ethical frameworks, societal design, and evidence-based medicine all play a crucial role in extending healthspan and improving quality of life.In this episode, you’ll learn:How geroscience can prevent multiple age-related diseases simultaneouslyThe ethical considerations of patient empowerment and longevity interventionsHow societal infrastructure and healthcare funding can support longer, healthier livesThe role of biomarkers and AI in safe, effective longevity strategiesThe future of integrated, evidence-based, and ethical longevity careIf you care about protecting your long-term health and want to understand how ethics, policy, and science intersect to shape the future of healthspan, this is a conversation you don’t want to miss.Subscribe for weekly episodes that explore longevity science, healthspan optimization, and the emerging technologies, policies, and strategies ________________Connect with our hosts:Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠ Dr. Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick explore the latest breakthroughs shaping healthspan and longevity, from new insights into genetic influence on lifespan to reproductive longevity, exosome therapeutics, AI health platforms, epigenetic reprogramming, and psychedelics for cognitive resilience.New research challenges long-standing estimates of genetic contribution to lifespan. When deaths caused by environmental factors are separated from intrinsic aging, heritability for intrinsic lifespan rises to around 50–55%, doubling previous assumptions and reshaping how we think about early interventions.Gameto licenses meiosis induction technology from Harvard to create ovarian organoids in a dish, opening a platform for women’s reproductive longevity, drug testing during pregnancy, and potentially improved menopause therapeutics.Houston-based Prana X Corp raises $17 million to develop exosome-based regenerative biologics, applying techniques initially developed for oncology toward healthy aging, inflammation reduction, and tissue repair.Digital health is evolving with AI concierge platforms like Death Clock and family-focused monitoring systems like Lufu, which track health data across households to drive actionable behavior change and support intergenerational wellbeing.Life Biosciences receives FDA approval for the first human trial of partial epigenetic reprogramming therapy ER100, targeting retinal cells in serious age-related eye disease. This milestone moves longevity science from theory to first-in-human application with the potential to expand to other organs and systemic age reversal.Psychedelics are re-emerging as potential tools for cognitive resilience and emotional health in older adults, with early studies showing unexpected benefits in Parkinson’s patients and implications for preventative approaches to mental health and neuroplasticity.______________________News & References:Genes reclaim center stage in longevity debate → https://longevity.technology/news/genes-reclaim-center-stage-in-longevity-debate/The regulatory path for rescheduling psychedelics for healthspan → https://longevity.technology/news/the-regulatory-path-for-rescheduling-psychedelics-for-healthspan/FDA clears first human trial of epigenetic reprogramming therapy → https://longevity.technology/news/fda-clears-first-human-trial-of-epigenetic-reprogramming-therapy/Death prediction app launches ‘AI health concierge’ → https://longevity.technology/news/death-prediction-app-launches-ai-health-concierge/Gameto licenses Harvard meiosis IP to advance human ovary‑in‑a‑dish platform → https://longevity.technology/news/gameto-licenses-harvard-meiosis-ip-to-advance-human-ovary-in-a-dish-platform/PranaX lands $17m to harness exosomes in regenerative biologics → https://longevity.technology/news/pranax-lands-17m-to-harness-exosomes-in-regenerative-biologics/______________________Hosts:Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

Guest:Dr Hany DemianCEO, Praesentia Healthcare Website: https://drdemian.com/ LinkedIn: https://www.linkedin.com/in/hany-demian-md-5b79b659/_________________What if chronic pain wasn’t just something to manage, but a key signal of deeper biological stress? And what if regenerative medicine could play a role in protecting long-term health and function?In conversation with Phil Newman and Dr. Nina Patrick, Dr. Hany Demian explores how regenerative medicine and peptide-based therapies are being used to support recovery, mobility, and healthy aging. He explains how chronic pain is often linked to inflammation, metabolic dysfunction, and impaired tissue repair rather than isolated injury.Dr. Demian highlights how tools such as PRP, peptides, cell-based therapies, and AI-assisted diagnostics can optimize repair, monitor progress, and guide personalized treatment plans, all while maintaining ethical, patient-centered care. The conversation shows how individualized protocols, informed by AI and clinical oversight, can improve outcomes without relying on one-size-fits-all solutions.This discussion reinforces that longevity is not only about supplements or exercise. Addressing pain, inflammation, and tissue health with precision medicine is a critical but often overlooked component of healthspan.In this episode, you’ll learn:How chronic pain affects long-term healthWhy regenerative approaches focus on repair, not symptom maskingThe role of AI and personalized treatment planningHow ethical oversight matters in regenerative careWhat the future of regenerative medicine may holdIf you care about protecting mobility, reducing chronic pain, and supporting long-term healthspan, this is a conversation you won’t want to miss.Subscribe for weekly episodes exploring longevity science, healthspan optimization, and emerging regenerative therapies.________________Connect with our hosts:Phil Newman: ⁠https://qrco.de/bgXpNY Dr. Nina Patrick: ⁠https://qrco.de/bgXpKn

The Longevity ShowWebsite: https://longevityshow.com/The Longevity Show is a science and wellness festival in London focused on healthy aging, cutting‑edge longevity research, practical health‑span strategies, expert talks, and an interactive expo.____________________In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick unpack the biggest stories shaping longevity science and technology, from epigenetic reprogramming and non-invasive brain therapies to AI-driven diagnostics.Elon Musk, speaking at Davos, suggested that aging is “very solvable,” framing it as an engineering challenge and emphasizing the growing mainstream awareness that biology can be engineered to extend healthspan.New research shows that sound stimulation at 40 Hz may help the brain clear toxic proteins linked to Alzheimer’s disease, offering a non-invasive, scalable approach to cognitive health if validated in humans.SimonMed launches longevity-focused MRI programs across the US, combining AI-enabled whole-body scans with lab testing and biomarkers to identify risks before symptoms arise.Researchers develop tiny wireless brain implants that can cross the blood-brain barrier without surgery, potentially transforming interventions for neurological aging and disease.Longevity has moved from lab benches to beauty counters, but as the category scales, experts warn that science-lite marketing could hollow it out.India’s Sun Pharma readies to launch generic semaglutide for weight management after patent expiry in 2026.____________________News & References:Elon Musk suggests aging is ‘very solvable’ → https://longevity.technology/news/elon-musk-suggests-aging-is-very-solvable/Non‑invasive sound therapy shows promise for Alzheimer’s → https://longevity.technology/news/non-invasive-sound-therapy-shows-promise-for-alzheimers/SimonMed launches longevity‑focused MRI program → https://longevity.technology/news/simonmed-launches-longevity-focused-mri-program/Sun Pharma gets approval for Wegovy-style weight loss shot → https://longevity.technology/news/sun-pharma-gets-approval-for-wegovy-style-weight-loss-shot/Brain implants may soon work without surgery → https://longevity.technology/news/brain-implants-may-soon-work-without-surgery/As longevity beauty grows, fears of ‘longevity washing’ rise → https://longevity.technology/news/as-longevity-beauty-grows-fears-of-longevity-washing-rise/____________________Connect with our hosts:Phil Newman: https://qrco.de/bgXpNYDr. Nina Patrick: https://qrco.de/bgXpKn

Guest: Dr Miguel StanleyFounder and clinical director of White ClinicWebsite: https://miguelstanley.com/Instagram: https://www.instagram.com/drmiguelstanley/?hl=enSponsor: The Longevity Show Website: https://longevityshow.com/ The Longevity Show is a science and wellness festival in London focused on healthy aging, cutting‑edge longevity research, practical health‑span strategies, expert talks, and an interactive expo.____________________What if your dentist could do more than just fix teeth? What if oral health became a key driver of long-term wellness and longevity?Phil Newman and Dr. Nina Patrick sit down with Miguel Stanley, a pioneer in longevity-focused dentistry. He explains how outdated dental work can create subclinical infections that contribute to systemic inflammation, impacting over 22 chronic diseases. Using CBCT imaging, strategic sequencing, and AI-assisted diagnostics, Miguel shows how modern dentistry can protect both healthspan and quality of life.He introduces revision dentistry, removing or updating old dental work that no longer supports health, and emphasizes ethical, patient-centered care. Patients who are informed and supported by AI can make smarter choices, while dentists can deliver more precise, preventive, and personalized care.This conversation highlights that longevity is not just about diet, supplements, or exercise. Oral health is a hidden lever for systemic wellness. With advanced diagnostics, treatment planning, and patient empowerment, dentistry can play a vital role in extending healthspan.In this episode, you’ll learn:How subclinical oral inflammation affects systemic healthWhy revision dentistry is critical for longevityThe role of AI in accurate diagnostics and patient empowermentHow sequencing dental treatments can optimize outcomesThe future of preventive, longevity-focused dentistryIf you care about protecting your long-term health and want to understand how oral care impacts your entire body, this is a conversation you don’t want to miss.Subscribe for weekly episodes that explore longevity science, healthspan optimization, and the emerging technologies and strategies shaping the future of preventive, longevity-focused dentistry.____________________Connect with our hosts:Phil Newman: https://qrco.de/bgXpNYDr. Nina Patrick: https://qrco.de/bgXpKn

The Longevity ShowWebsite: https://longevityshow.com/The Longevity Show is a science and wellness festival in London focused on healthy aging, cutting‑edge longevity research, practical health‑span strategies, expert talks, and an interactive expo.__________In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick unpack the biggest stories shaping longevity science and technology, from brain-computer interfaces and AI-driven diagnostics to spaceflight epigenetics and longevity event updates.Merge Labs, Sam Altman’s BCI startup, launches with funding from OpenAI, exploring next-generation neural interfaces that could merge human cognition with AI.Lumati introduces an at-home saliva microplastics test, giving individuals a practical way to track environmental exposure and its potential health impacts.Spaceflight research reveals dynamic DNA methylation changes in astronauts on the Axiom 2 mission, offering fast insights into biological aging and epigenetic plasticity.The Houstonian Hotel, Club & Spa has appointed Fountain Life as its exclusive partner for longevity and preventive health services.The Longevity Show 2026 gears up with NAD Clinic as an official Innovator Partner, plus new speakers announced, highlighting the convergence of longevity clinics, wellness, and technology.Investment momentum continues to accelerate across longevity ventures, reflecting growing interest in diagnostics, neurotech, and preventive health innovations.__________News & References:Sam Altman’s BCI startup Merge Labs launches with funding from OpenAI → https://longevity.technology/news/sam-altmans-bci-startup-merge-labs-launches-with-funding-from-openai/Lumati launches at-home saliva microplastics test → https://longevity.technology/news/lumati-launches-at-home-saliva-microplastics-test/NADclinic named Innovator Partner for The Longevity Show 2026 → https://longevity.technology/news/nadclinic-named-innovator-partner-for-the-longevity-show-2026/Longevity Show reveals second wave of speakers → https://longevity.technology/news/longevity-show-reveals-second-wave-of-speakers/SciNeuro and Novartis ink $1.7b deal for new Alzheimer’s treatment →https://longevity.technology/news/scineuro-and-novartis-ink-1-7b-deal-for-new-alzheimers-treatment/Fountain Life named exclusive longevity partner of Houstonian hotel and spa → https://longevity.technology/news/fountain-life-named-exclusive-longevity-partner-of-houstonian-hotel-and-spa/__________Hosts:Phil Newman: ⁠https://qrco.de/bgXpNY⁠Nina Patrick: ⁠https://qrco.de/bgXpKn⁠

Guests:Nabiha SaklayenCEO and Co-Founder of CellinoLinkedIn: https://www.linkedin.com/in/nabihasaklayen/Cellino: https://cellinobio.com/Vladik KrupalnikCEO and Co-Founder of RenewalBioLinkedIn: https://www.linkedin.com/in/vladik-krupalnik-0669b729/RenewalBio: https://www.renewal.bio/________What can regenerative medicine teach us about health, longevity, and personalized medicine?Phil Newman and Dr. Nina Patrick sit down with biotech pioneers Nabiha Saklayen and Vladik Krupalnik to explore how cutting-edge stem cell technologies are transforming medicine. They discuss how induced pluripotent stem cells (iPSCs) can be scaled for various applications, from rare blood disorders to organ-specific cells, and how these approaches could redefine healthspan and lifespan.Beyond individual treatments, Nabiha and Vladik share their visions for decentralized, on-demand cell manufacturing, regulatory strategies, and AI-driven platforms that could make personalized regenerative medicine accessible globally. They also highlight how infrastructure, standardization, and investor alignment are shaping the trajectory of longevity-focused biotech.This conversation combines the science of regenerative medicine with practical insights for anyone interested in extending healthspan, optimizing personalized therapies, and leveraging technology to transform medicine. Subscribe for weekly episodes on longevity science, regenerative medicine, and the innovations shaping our future.In this episode, you’ll learn:How iPSCs are being used to generate blood, liver, heart, and pancreatic cellsStepwise strategies for moving from preclinical work to first-in-human trialsThe distinction between science fiction and realistic regenerative therapiesHow decentralized manufacturing can safely bring therapies closer to patientsInvestor perspectives on longevity and regenerative medicineHow personalized cell therapies may eventually extend human healthspanIf you care about living longer and healthier, and you’re curious about how regenerative medicine could redefine personalized healthcare, this is a conversation you don’t want to miss.Subscribe for weekly episodes that explore longevity science, healthspan extension, and the breakthrough technologies shaping the future of regenerative and personalized medicine.__________Connect with our Hosts:Phil Newman: https://qrco.de/bgXpNY Dr. Nina Patrick: https://qrco.de/bgXpKn

Sponsor: The Longevity ShowWebsite: https://longevityshow.com/The Longevity Show is a science and wellness festival in London focused on healthy aging, cutting‑edge longevity research, practical health‑span strategies, expert talks, and an interactive expo.__________________In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick unpack the biggest stories shaping the longevity ecosystem, from breakthrough neurological therapeutics and pet longevity innovations to advances in neuroplasticity, wearable tech, and early-stage cardiovascular interventions.Vector Y’s ALS drug, VTX002, received Fast Track designation, targeting the TDP43 protein and marking a potential shift from symptom management to disease modification in ALS.Loyal’s senior dog longevity drug, LOY002, clears FDA safety hurdles, aiming to extend lifespan in large mammals while providing insights for human longevity applications.Cumulus introduces a scalable neuroplasticity measurement platform with wireless dry EEG sensors, allowing researchers to monitor brain adaptation and recovery in clinical settings efficiently.Significant investment activity continues in longevity-focused startups, including multi-million-dollar raises for cardiovascular disease prevention, extracellular matrix-targeted therapies, and regenerative biologics.__________________News & References:Vector Y wins FDA Fast Track for ALS therapy → https://longevity.technology/news/vectory-wins-fda-fast-track-for-als-therapy/FDA clears safety step for Loyal’s senior dog longevity drug → https://longevity.technology/news/fda-clears-safety-step-for-loyals-senior-dog-longevity-drug/Cumulus proves brain plasticity can be measured at scale → https://longevity.technology/news/cumulus-proves-brain-plasticity-can-be-measured-at-scale/Nvidia and Eli Lilly bet $1 billion on AI-powered drug discovery → https://longevity.technology/news/nvidia-and-eli-lilly-bet-1-billion-on-ai-powered-drug-discovery/50M boost secured for BioBeat’s wearable blood pressure tech → https://longevity.technology/news/50m-boost-secured-for-biobeats-wearable-blood-pressure-tech/Engitix raises $25M to target tissue aging at its source → https://longevity.technology/news/engitix-raises-25m-to-target-tissue-aging-at-its-source/Corsera lands $80M to predict and prevent cardiovascular disease → https://longevity.technology/news/corsera-lands-80m-to-predict-and-prevent-cardiovascular-disease/Proxima lands $80M to make protein interactions programmable → https://longevity.technology/news/proxima-lands-80m-to-make-protein-interactions-programmable/__________________Hosts:Phil Newman: https://qrco.de/bgXpNYNina Patrick: https://qrco.de/bgXpKn